MLL3 is a de novo cause of endocrine therapy resistance.
Kimberly M StaufferDavid L ElionRebecca S CookThomas P StrickerPublished in: Cancer medicine (2021)
Our data show that a decrease in functional MLL3 leads to endocrine therapy resistance. This highlights the importance of genotyping patient tumor samples for MLL3 mutation upon initial resection, prior to deciding upon treatment plans.